Chronic Obstructive Pulmonary Disease Drugs Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Disease Type (Emphysema, Chronic Bronchitis); Therapy (Bronchodilators, Steroids, Anti-inflammatory Drugs, Others); End User (Hospitals, Clinics, Others) and Geography

Report Code: TIPRE00016845 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Request Now
Happy to join you in your fight against the COVID-19 economic pandemic!
MARKET INTRODUCTION

Chronic obstructive pulmonary disease is a type of obstructive lung disease characterized by long-term breathing problems and low airflow. The primary symptoms include shortness of breath and cough with sputum production. Chronic obstructive pulmonary disease is a progressive disease, meaning it typically aggravates over time. The two different kinds of COPD are emphysema and chronic bronchitis. Chronic bronchitis is a productive cough present for at least three months each year for two years. The individuals with such a cough are at a greater risk of developing COPD. Emphysem is also used for the abnormal air or other gas within tissues. The most common cause is tobacco smoking, with a smaller number of cases due to air pollution and genetics. In the developing world, familiar sources of air pollution are wood combustion, and cooking fires. Moreover, long-term exposure to these risk factors causes an inflammatory reaction in the lungs, leading to narrowing of the small air passages and breakdown of lung tissue. COPD is diagnosed based on low airflow as measured by lung function tests.

MARKET DYNAMICS

The chronic obstructive pulmonary disease drug market has shown a significant evolution over the forecast period. The key driving factors include increased incidence and prevalence of COPD, technological advancements, and a growing aging population. As per the US Census Bureau's Statistics, as of 2020, the total number of people aged between 65 and older exceeded 50 million. According to the United Nations, during 2015-2030, the number of older persons aged 60 years or worldwide is projected to grow from 901 million to more than 1.4 billion. The significant factors that cause COPD are exposure to air pollution , cigarette smoke, rare genetic condition, chemical fumes or dust, among others. The Lancet Respiratory Medicine published an article in 2020, revealed that permanent lung tissue damage caused due to COPD begins even before the patient experiences any symptoms. Besides, technological advancements are anticipated to provide lucrative market opportunities. However, limitations of traditional treatments, such as late-onset of action and low efficacy, and stringent government regulations are likely to restrict the market growth.

MARKET SCOPE

The "Chronic Obstructive Pulmonary Disease Drugs Market Analysis to 2028" is a specialized and in-depth study of pharmaceuticals in the healthcare industry, focusing on the global market trend analysis. This report outlines the chronic obstructive pulmonary disease drugs market with detailed market segmentation by disease type, therapy, and end-user. The chronic obstructive pulmonary disease drug market is expected to witness high growth during the forecast period. The report focuses on the vital statistics on the market status of the leading players in the chronic obstructive pulmonary disease drugs market and offers key trends and opportunities.

MARKET SEGMENTATION

The market is segmented based on disease type, therapy, and end-user. Based on disease type, the market is categorized as emphysema and chronic bronchitis. Based on the therapy, the market is segmented as bronchodilators, steroids, anti-inflammatory drugs, and others. Based on the end-user, the market is segmented as hospitals, clinics, and others.

REGIONAL FRAMEWORK

The report lays out a detail outline of the industry, including both qualitative and quantitative information. The report gives a sketch and forecast of the chronic obstructive pulmonary disease drugs market based on various segments. It also consists of market size and forecast estimates from the year 2020 to2028 concerning five major regions: North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA), and South & Central America. The market by each region is then subsegmented into respective countries and segments. The report consists of the analysis and forecast of eighteen countries globally and the recent trend and opportunities prevailing in the region.

The report analyzes factors affecting the chronic obstructive pulmonary disease drug market from both the demand and supply side. Furthermore, it evaluates market dynamics affecting the market during the forecast period, i.e., drivers, restraints, opportunities, and future trends. The report also comprises of precise PEST analysis for all five regions, namely; North America, Europe, APAC, MEA, and South & Central America, after evaluating political, economic, social, and technological factors affecting the chronic obstructive pulmonary disease drugs market in these regions.



Get more information on this report :

MARKET PLAYERS


The report contains critical developments in the chronic obstructive pulmonary disease drugs market as organic and inorganic growth strategies. Various enterprises focus on organic growth strategies like product launches, product approvals, and others, such as patents and events. Inorganic growth strategies observed in the market were acquisitions and partnerships & collaborations. These activities have paved the way for the expansion of business and customer base of market players. The market players from the chronic obstructive pulmonary disease drugs market are anticipated to have profitable growth opportunities in the coming years with the rising demand for the chronic obstructive pulmonary disease drugs market globally. Given below is the list of few companies engaged in the chronic obstructive pulmonary disease drug market.

The report also consists of the profiles of key players in the chronic obstructive pulmonary disease drugs market, along with their SWOT analysis and market strategies. Additionally, the report elaborates on leading industry players with information on company profiles, components, and services provided, financial information of the last three years, critical development in the past five years.

  •  AstraZeneca
  •  Boehringer Ingelheim International GmbH
  •  Mylan N.V.
  •  Teva Pharmaceutical Industries Ltd
  •  GlaxoSmithKline plc
  •  Abbott
  •  Astellas Pharma
  •  Circassia Pharmaceuticals plc
  •  Pfizer Inc.
  •  F. Hoffmann-La Roche Ltd

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and provides various customization options in the current study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Chronic Obstructive Pulmonary Disease Drugs Market - By Disease Type
1.3.2 Chronic Obstructive Pulmonary Disease Drugs Market - By Therapy
1.3.3 Chronic Obstructive Pulmonary Disease Drugs Market - By End User
1.3.4 Chronic Obstructive Pulmonary Disease Drugs Market - By Region
1.3.4.1 By Country

2. KEY TAKEAWAYS

3. RESEARCH METHODOLOGY

4. CHRONIC OBSTRUCTIVE PULMONARY DISEASE DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS

5. CHRONIC OBSTRUCTIVE PULMONARY DISEASE DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS

6. CHRONIC OBSTRUCTIVE PULMONARY DISEASE DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. CHRONIC OBSTRUCTIVE PULMONARY DISEASE DRUGS - GLOBAL MARKET OVERVIEW
6.2. CHRONIC OBSTRUCTIVE PULMONARY DISEASE DRUGS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE

7. CHRONIC OBSTRUCTIVE PULMONARY DISEASE DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - DISEASE TYPE
7.1. OVERVIEW
7.2. DISEASE TYPE MARKET FORECASTS AND ANALYSIS
7.3. EMPHYSEMA
7.3.1. Overview
7.3.2. Emphysema Market Forecast and Analysis
7.4. CHRONIC BRONCHITIS
7.4.1. Overview
7.4.2. Chronic Bronchitis Market Forecast and Analysis
8. CHRONIC OBSTRUCTIVE PULMONARY DISEASE DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - THERAPY
8.1. OVERVIEW
8.2. THERAPY MARKET FORECASTS AND ANALYSIS
8.3. BRONCHODILATORS
8.3.1. Overview
8.3.2. Bronchodilators Market Forecast and Analysis
8.4. STEROIDS
8.4.1. Overview
8.4.2. Steroids Market Forecast and Analysis
8.5. ANTI-INFLAMMATORY DRUGS
8.5.1. Overview
8.5.2. Anti-inflammatory Drugs Market Forecast and Analysis
8.6. OTHERS
8.6.1. Overview
8.6.2. Others Market Forecast and Analysis
9. CHRONIC OBSTRUCTIVE PULMONARY DISEASE DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - END USER
9.1. OVERVIEW
9.2. END USER MARKET FORECASTS AND ANALYSIS
9.3. HOSPITALS
9.3.1. Overview
9.3.2. Hospitals Market Forecast and Analysis
9.4. CLINICS
9.4.1. Overview
9.4.2. Clinics Market Forecast and Analysis
9.5. OTHERS
9.5.1. Overview
9.5.2. Others Market Forecast and Analysis

10. CHRONIC OBSTRUCTIVE PULMONARY DISEASE DRUGS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Chronic Obstructive Pulmonary Disease Drugs Market Overview
10.1.2 North America Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis
10.1.3 North America Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis - By Disease Type
10.1.4 North America Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis - By Therapy
10.1.5 North America Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis - By End User
10.1.6 North America Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis - By Countries
10.1.6.1 United States Chronic Obstructive Pulmonary Disease Drugs Market
10.1.6.1.1 United States Chronic Obstructive Pulmonary Disease Drugs Market by Disease Type
10.1.6.1.2 United States Chronic Obstructive Pulmonary Disease Drugs Market by Therapy
10.1.6.1.3 United States Chronic Obstructive Pulmonary Disease Drugs Market by End User
10.1.6.2 Canada Chronic Obstructive Pulmonary Disease Drugs Market
10.1.6.2.1 Canada Chronic Obstructive Pulmonary Disease Drugs Market by Disease Type
10.1.6.2.2 Canada Chronic Obstructive Pulmonary Disease Drugs Market by Therapy
10.1.6.2.3 Canada Chronic Obstructive Pulmonary Disease Drugs Market by End User
10.1.6.3 Mexico Chronic Obstructive Pulmonary Disease Drugs Market
10.1.6.3.1 Mexico Chronic Obstructive Pulmonary Disease Drugs Market by Disease Type
10.1.6.3.2 Mexico Chronic Obstructive Pulmonary Disease Drugs Market by Therapy
10.1.6.3.3 Mexico Chronic Obstructive Pulmonary Disease Drugs Market by End User
10.2. EUROPE
10.2.1 Europe Chronic Obstructive Pulmonary Disease Drugs Market Overview
10.2.2 Europe Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis
10.2.3 Europe Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis - By Disease Type
10.2.4 Europe Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis - By Therapy
10.2.5 Europe Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis - By End User
10.2.6 Europe Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Chronic Obstructive Pulmonary Disease Drugs Market
10.2.6.1.1 Germany Chronic Obstructive Pulmonary Disease Drugs Market by Disease Type
10.2.6.1.2 Germany Chronic Obstructive Pulmonary Disease Drugs Market by Therapy
10.2.6.1.3 Germany Chronic Obstructive Pulmonary Disease Drugs Market by End User
10.2.6.2 France Chronic Obstructive Pulmonary Disease Drugs Market
10.2.6.2.1 France Chronic Obstructive Pulmonary Disease Drugs Market by Disease Type
10.2.6.2.2 France Chronic Obstructive Pulmonary Disease Drugs Market by Therapy
10.2.6.2.3 France Chronic Obstructive Pulmonary Disease Drugs Market by End User
10.2.6.3 Italy Chronic Obstructive Pulmonary Disease Drugs Market
10.2.6.3.1 Italy Chronic Obstructive Pulmonary Disease Drugs Market by Disease Type
10.2.6.3.2 Italy Chronic Obstructive Pulmonary Disease Drugs Market by Therapy
10.2.6.3.3 Italy Chronic Obstructive Pulmonary Disease Drugs Market by End User
10.2.6.4 Spain Chronic Obstructive Pulmonary Disease Drugs Market
10.2.6.4.1 Spain Chronic Obstructive Pulmonary Disease Drugs Market by Disease Type
10.2.6.4.2 Spain Chronic Obstructive Pulmonary Disease Drugs Market by Therapy
10.2.6.4.3 Spain Chronic Obstructive Pulmonary Disease Drugs Market by End User
10.2.6.5 United Kingdom Chronic Obstructive Pulmonary Disease Drugs Market
10.2.6.5.1 United Kingdom Chronic Obstructive Pulmonary Disease Drugs Market by Disease Type
10.2.6.5.2 United Kingdom Chronic Obstructive Pulmonary Disease Drugs Market by Therapy
10.2.6.5.3 United Kingdom Chronic Obstructive Pulmonary Disease Drugs Market by End User
10.2.6.6 Rest of Europe Chronic Obstructive Pulmonary Disease Drugs Market
10.2.6.6.1 Rest of Europe Chronic Obstructive Pulmonary Disease Drugs Market by Disease Type
10.2.6.6.2 Rest of Europe Chronic Obstructive Pulmonary Disease Drugs Market by Therapy
10.2.6.6.3 Rest of Europe Chronic Obstructive Pulmonary Disease Drugs Market by End User
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Chronic Obstructive Pulmonary Disease Drugs Market Overview
10.3.2 Asia-Pacific Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis
10.3.3 Asia-Pacific Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis - By Disease Type
10.3.4 Asia-Pacific Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis - By Therapy
10.3.5 Asia-Pacific Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis - By End User
10.3.6 Asia-Pacific Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Chronic Obstructive Pulmonary Disease Drugs Market
10.3.6.1.1 Australia Chronic Obstructive Pulmonary Disease Drugs Market by Disease Type
10.3.6.1.2 Australia Chronic Obstructive Pulmonary Disease Drugs Market by Therapy
10.3.6.1.3 Australia Chronic Obstructive Pulmonary Disease Drugs Market by End User
10.3.6.2 China Chronic Obstructive Pulmonary Disease Drugs Market
10.3.6.2.1 China Chronic Obstructive Pulmonary Disease Drugs Market by Disease Type
10.3.6.2.2 China Chronic Obstructive Pulmonary Disease Drugs Market by Therapy
10.3.6.2.3 China Chronic Obstructive Pulmonary Disease Drugs Market by End User
10.3.6.3 India Chronic Obstructive Pulmonary Disease Drugs Market
10.3.6.3.1 India Chronic Obstructive Pulmonary Disease Drugs Market by Disease Type
10.3.6.3.2 India Chronic Obstructive Pulmonary Disease Drugs Market by Therapy
10.3.6.3.3 India Chronic Obstructive Pulmonary Disease Drugs Market by End User
10.3.6.4 Japan Chronic Obstructive Pulmonary Disease Drugs Market
10.3.6.4.1 Japan Chronic Obstructive Pulmonary Disease Drugs Market by Disease Type
10.3.6.4.2 Japan Chronic Obstructive Pulmonary Disease Drugs Market by Therapy
10.3.6.4.3 Japan Chronic Obstructive Pulmonary Disease Drugs Market by End User
10.3.6.5 South Korea Chronic Obstructive Pulmonary Disease Drugs Market
10.3.6.5.1 South Korea Chronic Obstructive Pulmonary Disease Drugs Market by Disease Type
10.3.6.5.2 South Korea Chronic Obstructive Pulmonary Disease Drugs Market by Therapy
10.3.6.5.3 South Korea Chronic Obstructive Pulmonary Disease Drugs Market by End User
10.3.6.6 Rest of Asia-Pacific Chronic Obstructive Pulmonary Disease Drugs Market
10.3.6.6.1 Rest of Asia-Pacific Chronic Obstructive Pulmonary Disease Drugs Market by Disease Type
10.3.6.6.2 Rest of Asia-Pacific Chronic Obstructive Pulmonary Disease Drugs Market by Therapy
10.3.6.6.3 Rest of Asia-Pacific Chronic Obstructive Pulmonary Disease Drugs Market by End User
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Market Overview
10.4.2 Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis
10.4.3 Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis - By Disease Type
10.4.4 Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis - By Therapy
10.4.5 Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis - By End User
10.4.6 Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Chronic Obstructive Pulmonary Disease Drugs Market
10.4.6.1.1 South Africa Chronic Obstructive Pulmonary Disease Drugs Market by Disease Type
10.4.6.1.2 South Africa Chronic Obstructive Pulmonary Disease Drugs Market by Therapy
10.4.6.1.3 South Africa Chronic Obstructive Pulmonary Disease Drugs Market by End User
10.4.6.2 Saudi Arabia Chronic Obstructive Pulmonary Disease Drugs Market
10.4.6.2.1 Saudi Arabia Chronic Obstructive Pulmonary Disease Drugs Market by Disease Type
10.4.6.2.2 Saudi Arabia Chronic Obstructive Pulmonary Disease Drugs Market by Therapy
10.4.6.2.3 Saudi Arabia Chronic Obstructive Pulmonary Disease Drugs Market by End User
10.4.6.3 U.A.E Chronic Obstructive Pulmonary Disease Drugs Market
10.4.6.3.1 U.A.E Chronic Obstructive Pulmonary Disease Drugs Market by Disease Type
10.4.6.3.2 U.A.E Chronic Obstructive Pulmonary Disease Drugs Market by Therapy
10.4.6.3.3 U.A.E Chronic Obstructive Pulmonary Disease Drugs Market by End User
10.4.6.4 Rest of Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Market
10.4.6.4.1 Rest of Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Market by Disease Type
10.4.6.4.2 Rest of Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Market by Therapy
10.4.6.4.3 Rest of Middle East and Africa Chronic Obstructive Pulmonary Disease Drugs Market by End User
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Chronic Obstructive Pulmonary Disease Drugs Market Overview
10.5.2 South and Central America Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis
10.5.3 South and Central America Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis - By Disease Type
10.5.4 South and Central America Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis - By Therapy
10.5.5 South and Central America Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis - By End User
10.5.6 South and Central America Chronic Obstructive Pulmonary Disease Drugs Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Chronic Obstructive Pulmonary Disease Drugs Market
10.5.6.1.1 Brazil Chronic Obstructive Pulmonary Disease Drugs Market by Disease Type
10.5.6.1.2 Brazil Chronic Obstructive Pulmonary Disease Drugs Market by Therapy
10.5.6.1.3 Brazil Chronic Obstructive Pulmonary Disease Drugs Market by End User
10.5.6.2 Argentina Chronic Obstructive Pulmonary Disease Drugs Market
10.5.6.2.1 Argentina Chronic Obstructive Pulmonary Disease Drugs Market by Disease Type
10.5.6.2.2 Argentina Chronic Obstructive Pulmonary Disease Drugs Market by Therapy
10.5.6.2.3 Argentina Chronic Obstructive Pulmonary Disease Drugs Market by End User
10.5.6.3 Rest of South and Central America Chronic Obstructive Pulmonary Disease Drugs Market
10.5.6.3.1 Rest of South and Central America Chronic Obstructive Pulmonary Disease Drugs Market by Disease Type
10.5.6.3.2 Rest of South and Central America Chronic Obstructive Pulmonary Disease Drugs Market by Therapy
10.5.6.3.3 Rest of South and Central America Chronic Obstructive Pulmonary Disease Drugs Market by End User

11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS

12. CHRONIC OBSTRUCTIVE PULMONARY DISEASE DRUGS MARKET, KEY COMPANY PROFILES
12.1. ASTRAZENECA
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. BOEHRINGER INGELHEIM INTERNATIONAL GMBH
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. MYLAN N.V.
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. TEVA PHARMACEUTICAL INDUSTRIES LTD
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. GLAXOSMITHKLINE PLC
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. ABBOTT
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. ASTELLAS PHARMA
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. CIRCASSIA PHARMACEUTICALS PLC
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. PFIZER INC.
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. F. HOFFMANN-LA ROCHE LTD
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments

13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

1. AstraZeneca
2. Boehringer Ingelheim International GmbH
3. Mylan N.V.
4. Teva Pharmaceutical Industries Ltd
5. GlaxoSmithKline plc
6. Abbott
7. Astellas Pharma
8. Circassia Pharmaceuticals plc
9. Pfizer Inc.
10. F. Hoffmann-La Roche Ltd
TIPRE00016845
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking